<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01274091</url>
  </required_header>
  <id_info>
    <org_study_id>28//2010</org_study_id>
    <nct_id>NCT01274091</nct_id>
  </id_info>
  <brief_title>Gene - Diet Interactions</brief_title>
  <acronym>Genediet</acronym>
  <official_title>Gene-diet Interactions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marjukka Kolehmainen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Eastern Finland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interactions between genes and environment, i.e. our inherited responses to environmental
      changes, may be crucial in the development of the common diseases. The investigators were the
      first to identify PPARG gene as risk gene for type 2 diabetes. The role of the Pro12Ala
      polymorphism in diabetes risk has also been verified in meta-analysis. However, this effect
      on seems to depend on intervention and age. In this study the effects of diets high with
      saturated fatty acids (SAFA) and polyunsaturated fatty acids (PUFA) are compared in subjects
      carrying either Pro12Pro or Ala12Ala genotype of the PPARG gene.

      Aim of the study:

      To test if subjects with Pro12Pro and Ala12Ala genotypes respond differentially to a diet
      supplemented with high saturated (SAFA) or polyunsaturated fat (PUFA).

      Hypotheses:

        1. Specific: Subjects with the Ala12Ala genotype will be more sensitive to dietary
           modification, and therefore respond more favorably to PUFA diet

        2. More general: Dietary instructions individually tailored according to the genotype would
           allow better treatment of obesity and diabetes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity and type 2 diabetes are increasing in all western countries, including Finland.
      Recent genome wide analyses have found &gt; 30 genes that contribute to either condition..
      However, none of these genes explain &gt;5% of the disease risk and altogether they explain &lt;
      10% of the total disease risk in cross-sectional studies. Therefore, diet and physical
      activity are still the major determinants of the risk, as demonstrated by our earlier
      intervention studies in order to find out the effect of different dietary modifications on
      glucose and lipid metabolism. More importantly, interactions between genes and environment,
      i.e. our inherited responses to environmental changes, may be crucial in the development of
      the common diseases. Unfortunately, gene-environment interaction can only be effectively
      investigated in intervention studies that are more expensive than cross-sectional population
      screenings. This leads to a lower sample size and reduced power to detect effects of minor
      alleles. Despite these limitations the investigators have been able to demonstrate
      gene-intervention interactions for several genes, including PPARG, in the Finnish Diabetes
      Prevention study. There is an urgent need for studies investigating effects of tailored diets
      in individuals selected based on their genotype. This will be the next essential step leading
      to improved dietary treatments guided by genetic information.

      The investigators were the first to identify PPARG gene as risk gene for type 2 diabetes. The
      role of the Pro12Ala polymorphism in diabetes risk has also been verified in meta-analysis.
      However, this effect on seems to depend on intervention and age. Based on these findings the
      investigators created in collaboration with Johan Auwerx an Pro12Ala animal model that
      demonstrated a differential effect of dietary fat composition depending on the genotype.
      However, an important conclusive proof that subjects selected based on their Pro12Ala
      genotype would respond differently to specifically tailored diet modification is still
      needed.

      In this study the effects of diets high with saturated fatty acids (SAFA) and polyunsaturated
      fatty acids (PUFA) are compared in subjects carrying either Pro12Pro or Ala12Ala genotype of
      the PPARG gene. As a primary endpoint the investigators expect insulin sensitivity to alter
      differently depending on the genotype. Additionally, a detailed characterization of energy,
      glucose and lipid metabolism will be performed. Because PPARG gene plays a central role in
      adipogenesis one of the aims of this study is to find new pathways, genes and gene clusters
      that are regulated by PPARG in humans.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>week 0</time_frame>
    <description>insulin sensitivity measured by oral glucose tolerance test at the beginning of the first, randomised diet</description>
  </primary_outcome>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>week 8</time_frame>
    <description>insulin sensitivty measured by oral glucose tolerance test after the first diet</description>
  </primary_outcome>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>week 10</time_frame>
    <description>Insulin sensitivity measured by oral glucose tolerance test in the beginning of the second, randomised diet</description>
  </primary_outcome>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>week 18</time_frame>
    <description>insulin sensitivity measured by oral glucose tolerance test after the second diet</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>peripheral blood mononuclear cell gene expression</measure>
    <time_frame>week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peripheral blood mononuclear cell gene expression</measure>
    <time_frame>week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum lipids</measure>
    <time_frame>week 8</time_frame>
    <description>serum lipids, including serum lipidomics and fatty acid composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum lipids</measure>
    <time_frame>week 18</time_frame>
    <description>serum lipids, including serum lipidomics and fatty acid composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammation</measure>
    <time_frame>week 8</time_frame>
    <description>inflammation measured as serum cytokines and adipose tissue inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammation</measure>
    <time_frame>week 18</time_frame>
    <description>inflammation measured as serum cytokines and adipose tissue inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>energy expenditure</measure>
    <time_frame>week 8</time_frame>
    <description>energy expenditure and the rates of substrate oxidation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>energy expenditure</measure>
    <time_frame>week 18</time_frame>
    <description>energy expenditure and the rates of substrate oxidation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin secretion</measure>
    <time_frame>week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin secretion</measure>
    <time_frame>week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adipose tissue gene expression</measure>
    <time_frame>week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adipose tissue gene expression</measure>
    <time_frame>week 18</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>P/S-ratio 1.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:
polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P/S-ration 0.3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:. Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PUFA-diet</intervention_name>
    <description>Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.</description>
    <arm_group_label>P/S-ratio 1.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SAFA-diet</intervention_name>
    <description>Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.</description>
    <arm_group_label>P/S-ration 0.3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt;20kg/m2 &lt;29kg/m2

          -  Pro12Pro and Ala12Ala genotypes of PPARG Pro12Ala polymorphism

          -  participation to METSIM-study (METabolic Syndrome in Men, currently &gt;10000 men
             included from the population living in Kuopio, principal investigator Markku Laakso)

          -  normoglycemia

        Exclusion Criteria:

          -  type 2 diabetes

          -  other chronic diseases
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jussi Pihlajam√§ki, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Eastern Finland, Kuopio University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ursula S Schwab, Clinical Lect, adjunct prof</last_name>
    <role>Study Director</role>
    <affiliation>University of Eastern Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matti Uusitupa, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Eastern Finland</name>
      <address>
        <city>Kuopio</city>
        <zip>FIN-70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2011</study_first_posted>
  <last_update_submitted>April 16, 2012</last_update_submitted>
  <last_update_submitted_qc>April 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Eastern Finland</investigator_affiliation>
    <investigator_full_name>Marjukka Kolehmainen</investigator_full_name>
    <investigator_title>Senior scientist</investigator_title>
  </responsible_party>
  <keyword>Gene-diet interaction</keyword>
  <keyword>PPARgamma gene</keyword>
  <keyword>Pro12Ala</keyword>
  <keyword>Fatty acids</keyword>
  <keyword>Dietary modification</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Glucose metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

